PO-1028: Consolidation therapy with Durvalumab after radical CRT in stage IIII NSCLC: a preliminar analysis. (November 2020) - Borghetti, P.; Volpi, G.; Imbrescia, J.; Bonù, M.L.; Guerini, A.; Turla, O.; Maddalo, M.; Vitali, P.; Triggiani, L.; Donofrio, A.; Buglione, M.; Magrini, S.M.